Baxter Announces CE Mark & Regulatory Approval of New Evo IQ Infusion System for the United Kingdom, Ireland, Australia & New...
August 01 2018 - 8:59AM
Business Wire
- Delivers a state-of-the-art system with
proven Dose IQ Safety Software to help elevate the standard
of patient safety
- User-friendly infusion system built to
deliver intuitive clinical workflows and help optimize clinician
efficiency
- Exclusive integration with One Set
System to help save nursing time and reduce opportunities for
contamination
Baxter International Inc. (NYSE:BAX), a leader in innovative
technology for medication delivery, today announced the CE marking
of the Evo IQ Infusion System. In addition to the planned
marketing of the device in the United Kingdom, Ireland and New
Zealand, the Evo IQ Infusion System recently received
regulatory approval by the Therapeutic Goods Administration (TGA)
in Australia. These markets represent the first in a series of
planned regulatory submissions for the Evo IQ Infusion
System in countries around the world, with commercial launch
activities starting in the third quarter of 2018.
The Evo IQ Infusion System features a scalable platform
and user-centric design that includes an advanced drug library and
dose error reduction software to promote patient safety; intuitive
clinical workflows to help optimize clinician efficiency; and
Baxter’s One Set technology, which allows clinicians to easily
switch between gravity and pump applications without changing sets,
reducing disconnects and set changes and may help reduce
opportunities for touch contamination, along with helping to reduce
IV tubing use and costs.
“With the Evo IQ Infusion System, Baxter is extending its
leading-edge infusion systems technology to help increase drug
library compliance and protect patient infusions in the UK,
Ireland, Australia, and New Zealand,” said David Ferguson, general
manager, Medication Delivery, Baxter. “The Evo IQ Infusion
System provides healthcare facilities with access to Baxter’s
proven infusion safety technology in an adaptable system that can
grow with their needs.”
Designed to Promote Patient Safety through Drug Library
Compliance
Drug libraries are the defining feature of smart pumps, designed
to help clinicians identify infusion pump programming errors. The
drug library allows hospitals to curate a list of medications and
fluids and set medically appropriate dose ranges. If programming
goes beyond the limits specified for that medication, smart
infusion pumps—like the Evo IQ Infusion System—will alert
clinicians before they administer the medication and in some cases,
prevent the delivery of the medication.
Every Evo IQ Infusion System works with Baxter’s
customizable Dose IQ safety software to streamline
programming steps and help reduce the chance of error and is
designed to facilitate effective use of drug libraries,
including:
- Simplifying and expediting the hospital
pharmacy’s drug library creation with support from a Baxter
specialist
- Automatically defaulting to the drug
library when powered on and requiring fewer programming steps to
start an infusion
- Providing dosing feedback at the point
of use, including drug name and both soft and hard safety
limits
- Enabling easy drug library updates to
help ensure programming is based on the most up-to-date
parameters
Engineered to Provide a High Standard of Efficiency
At launch, the Evo IQ Infusion System will include a
large volumetric infusion pump, with a pipeline of complementary
technology to launch in the future, including additional pump and
set offerings that will enable healthcare facilities to expand and
upgrade the Evo IQ platform. Other Evo IQ Infusion
System features designed to help increase hospital efficiency
include:
- A modular and upgradable design, with
features that make training faster and can potentially reduce
implementation, training and servicing costs
- Lightweight and portable pumps with
stacking and docking station options that are easy to move, clean,
maintain and set up
- Clear organization of critical infusion
parameters on screen
- Prioritized alarms differentiated by
severity to help reduce alarm fatigue
For more information on the Evo IQ Infusion System,
please visit www.EvoIQInfusion.com.
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s
leading portfolio of critical care, nutrition, renal, hospital and
surgical products. For more than 85 years, we’ve been
operating at the critical intersection where innovations that save
and sustain lives meet the healthcare providers that make it
happen. With products, technologies and therapies available in
more than 100 countries, Baxter’s employees worldwide are now
building upon the company’s rich heritage of medical breakthroughs
to advance the next generation of transformative healthcare
innovations. To learn more, visit www.baxter.com and
follow us
on Twitter, LinkedIn and Facebook.
For safe and proper use of this device, refer to the full
Instructions for Use.
This release includes forward-looking statements concerning
Baxter’s Evo IQ Infusion System and Dose IQ Safety Software,
including potential benefits associated with their use. The
statements are based on assumptions about many important factors,
including the following, which could cause actual results to differ
materially from those in the forward-looking statements:
satisfaction of regulatory and other requirements; actions of
regulatory bodies and other governmental authorities; product
quality, manufacturing or supply, or patient safety issues; changes
in law and regulations; and other risks identified in Baxter's most
recent filing on Form 10-K and other SEC filings, all of which are
available on Baxter's website. Baxter does not undertake to update
its forward-looking statements.
Baxter, Evo IQ and Dose IQ are registered
trademarks of Baxter International Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180801005519/en/
Baxter International Inc.Media ContactEric Tatro, (224)
948-5353media@baxter.comorInvestor ContactClare Trachtman, (224)
948-3085
Baxter (NYSE:BAX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Baxter (NYSE:BAX)
Historical Stock Chart
From Sep 2023 to Sep 2024